ProCE Banner Activity

How New Data From IAS 2017 May Inform Dual-Therapy Options for HIV Treatment

Clinical Thought
Should dual-therapy ART be considered in the first-line setting for some patients?

Released: September 12, 2017

Expiration: September 11, 2018

No longer available for credit.

Share

Faculty

Danielle Roman

Danielle Roman, PharmD, BCOP

Manager, Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

ViiV Healthcare

Faculty Disclosure

Primary Author

Danielle Roman, PharmD, BCOP

Manager, Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Gilead Sciences, GlaxoSmithKline, Janssen, Merck, and ViiV and funds for research support from Abbott, Gilead Sciences, and Merck.